Seres Therapeutics, Inc.
NASDAQ:MCRBBiotechnology
+$0.11 today
- Market cap
- $51.13M
- Beta
- 0.11
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$4.89
Volume 0.04M
Average 0.06M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Seres Therapeutics, Inc.
NASDAQ:MCRB
Intrinsic Alpha fair value
Locked
Current Price
$5.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | -7.1% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at -7.1% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Opus Genetics, Inc. NASDAQ:IRD | $385.58M | $4.67 | Not rated | -33.0 | +111.40% |
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | $229.68M | $3.18 | Not rated | -1.3 | +46.79% |
TuHURA Biosciences, Inc. NASDAQ:HURA | $136.28M | $2.14 | Not rated | -4.6 | -14.47% |
Seer, Inc. NASDAQ:SEER | $107.21M | $1.95 | Not rated | -1.4 | -28.61% |
Inovio Pharmaceuticals, Inc. NASDAQ:INO | $98.80M | $1.43 | Not rated | -8.9 | -1.16% |
Cognition Therapeutics, Inc. NASDAQ:CGTX | $92.18M | $1.03 | Not rated | -6.4 | -54.84% |
Spero Therapeutics, Inc. NASDAQ:SPRO | $70.06M | $1.21 | Undervalued | 8.2 | -61.33% |
Actuate Therapeutics Inc NASDAQ:ACTU | $35.41M | $1.48 | Not rated | -2.3 | -65.68% |
Continue the stock analysis
Jump to another research area for this company.